Mike Hooven, Founder of AtriCure (NASDAQ: ATRC) and Enable Injections, Joins Genetesis Board of Directors
October 11 2017 - 11:11AM
Business Wire
Veteran Medical Device Entrepreneur Adds
Experience, Connections to Cardiac Imaging Startup
Genetesis, a medical technology company that gives doctors an
accurate, non-invasive tool for seeing how the heart beats,
announces the addition of Mike Hooven to its Board of
Directors.
Hooven is a serial medical device entrepreneur, engineer and
product design expert with over 30 years of experience founding
transformative companies including AtriCure (NASDAQ:ATRC) and
Enable Injections. He holds more than 100 issued and pending US
patents.
“I am delighted to be joining the Genetesis team. They are
creating a completely new way to see and diagnose what is going on
inside the human body,” said Hooven. “I am looking forward to
providing whatever insight and experience I can to guide them on
this very exciting journey.”
Genetesis is developing CardioFlux™, a biomagnetic imaging
device, to revolutionize chest pain triage in hospital emergency
departments. Currently, the widely used electrocardiogram (ECG or
EKG) provides a snapshot of heart rate and rhythm during the test,
but does not reflect many underlying problems that may exist when a
patient is not experiencing symptoms. CardioFlux™ gives physicians
3D mapping tools, to understand each patient’s underlying
electrical activity, which can potentially be used to diagnose,
characterize, and guide treatment for a variety of cardiac
disorders.
Since closing a seed financing from investors including Mark
Cuban and CincyTech, Genetesis has presented findings from a
collaboration with the Mayo Clinic, and started a clinical study at
St. John Hospital and Medical Center in Detroit. Genetesis won the
Nvidia Inception Award for “Best AI Social Impact Startup,” and was
named VentureOhio’s Seed Stage Company of the Year.
“Mike Hooven is one of the foremost medical device innovators in
the Midwest. His track record of building companies like AtriCure
and Enable Injections speaks for itself,” said Genetesis CEO
Peeyush Shrivastava. “He brings decades of successful medical
device operating experience and tremendous value to our Board.”
ABOUT GENETESIS
Genetesis is a medical technology company developing
CardioFlux™, a non-invasive platform using magnetic measurements to
map the heart’s electrical currents for detection and treatment of
cardiovascular disease.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171011005815/en/
GenetesisPeeyush Shrivastavapeeyush@genetesis.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2023 to Apr 2024